ReviewClinical & translational immunology2020
Enhancing the efficacy of immunotherapy using radiotherapy.
Review in Clinical & translational immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Pooled it
- Enhanced Sonodynamic Therapy and Radiotherapy Efficacy: Modified Polyethylene Glycol-Bismuth Trioxide Nanoplatform for Targeted Tumor Treatment.Biomaterials research · 2026Article
- Role of Fruit-Derived Antioxidants in Fighting Cancer: A Narrative Review.Indian journal of clinical biochemistry : IJCB · 2025Review
- Immunomodulatory nanoplatforms with multiple mechanisms of action in cancer treatment.Nanomedicine (London, England) · 2025Review
- Fractionated low-dose radiotherapy primes the tumor microenvironment for immunotherapy in a murine mesothelioma model.Cancer immunology, immunotherapy : CII · 2025Article
- Leveraging radiotherapy to improve immunotherapy outcomes: rationale, progress and research priorities.Clinical & translational immunology · 2025Review
- Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective.International journal of colorectal disease · 2024Review
- A combination of lymphatic drug delivery of anti-CTLA-4 antibody and local radiotherapy for solid-tumor treatment.Cancer science · 2024Article
- Double-Faced Immunological Effects of CDK4/6 Inhibitors on Cancer Treatment: Challenges and Perspectives.Bioengineering (Basel, Switzerland) · 2024Review
- Biological Insights and Radiation-Immuno-Oncology Developments in Primary and Secondary Brain Tumors.Cancers · 2024Review
- Manganese-based nanomaterials in diagnostics and chemodynamic therapy of cancers: new development.RSC advances · 2024Review
- Antitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models.Cell death & disease · 2024Article
- Peripheral Blood CD8Clinical Medicine Insights. Oncology · 2024Article
- Intratumoral nanofluidic system enhanced tumor biodistribution of PD-L1 antibody in triple-negative breast cancer.Bioengineering & translational medicine · 2023Article
- Adjuvant radiotherapy after salvage surgery for melanoma recurrence in a node field following a previous lymph node dissection.Journal of surgical oncology · 2023Article
- Targeting oral tumor microenvironment for effective therapy.Cancer cell international · 2023Review
- Dissecting the role of the gut microbiome and fecal microbiota transplantation in radio- and immunotherapy treatment of colorectal cancer.Frontiers in cellular and infection microbiology · 2023Review
- Article
- Preclinical Study ofCells · 2022Article
- Clinical evidence for synergy between immunotherapy and radiotherapy (SITAR).Journal of medical imaging and radiation oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent clinical breakthroughs in cancer immunotherapy, especially with immune checkpoint blockade, offer great hope for cancer sufferers - and have greatly changed the landscape of cancer treatment. However, whilst many patients achieve clinical responses, others experience minimal benefit or do not respond to immune checkpoint blockade at all. Researchers are therefore exploring multimodal approaches by combining immune checkpoint blockade with conventional cancer therapies to enhance the efficacy of treatment. A growing body of evidence from both preclinical studies and clinical observations indicates that radiotherapy could be a powerful driver to augment the efficacy of immune checkpoint blockade, because of its ability to activate the antitumor immune response and potentially overcome resistance. In this review, we describe how radiotherapy induces DNA damage and apoptosis, generates immunogenic cell death and alters the characteristics of key immune cells in the tumor microenvironment. We also discuss recent preclinical work and clinical trials combining radiotherapy and immune checkpoint blockade in thoracic and other cancers. Finally, we discuss the scheduling of immune checkpoint blockade and radiotherapy, biomarkers predicting responses to combination therapy, and how these novel data may be translated into the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.